Frequency Therapeutics Inc logo

FREQ - Frequency Therapeutics Inc Share Price

$20.74 1.0  4.9%

Last Trade - 8:43pm

Sector
Healthcare
Size
Mid Cap
Market Cap £488.9m
Enterprise Value £359.2m
Revenue £19.5m
Position in Universe 2453rd / 6323
Bullish
Bearish
Unlock FREQ Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

FREQ Revenue Unlock FREQ Revenue

Net Income

FREQ Net Income Unlock FREQ Revenue

Normalised EPS

FREQ Normalised EPS Unlock FREQ Revenue

PE Ratio Range

FREQ PE Ratio Range Unlock FREQ Revenue

Dividend Yield Range

FREQ Dividend Yield Range Unlock FREQ Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
FREQ EPS Forecasts Unlock FREQ Revenue
Profile Summary

Frequency Therapeutics Inc. is a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair and reverse damage caused by a broad range of degenerative diseases. It is a progenitor cell activation (PCA) regeneration company, which is focused on developing small molecule drugs that activate progenitor cells within the body to restore healthy tissue. It uses its PCA technology to develop a pipeline of progenitor cell activators. It focuses on various therapeutic areas, such as hearing loss (sensorineural hearing loss- SNHL), skin and bone disorders, muscle regeneration, and gastrointestinal tract diseases. Its pipeline program are FX-322, which activates the regrowth of sensory cells in the inner ear to treat chronic noise induced hearing loss; and Multiple sclerosis (MS). It has initiated a discovery program in MS after identifying MS as a degenerative disease that has the potential to be treated with small molecules that activate progenitor cells.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated November 13, 2014
Public Since October 3, 2019
No. of Shareholders: n/a
No. of Employees: 37
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 30,784,936
Free Float (0.0%)
Eligible for
ISAs
SIPPs
FREQ Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for FREQ
Upcoming Events for FREQ
Similar to FREQ
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.